[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-diabetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-diabetic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609306","phase-1-the-role-of-glucagon-in-glucose-metabolism-in-humans-with-and-without-bariatric-surgery-100609306",false,"NCT07212868","The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form from participant.\n2. Male or female, ≤65 and ≥18 years old\n3. Subjects with history of gastric bypass surgery and sleeve gastrectomy more than a year since surgery and non-surgical subjects without history of gastrointestinal (GI) surgery\n4. HbA1c ≤6%\n5. Willing to adhere to the study intervention regimen\n6. Female subjects of childbearing potential must have a negative pregnancy test at screening and all the study visits, and must not be lactating\n7. Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions during the study.It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.\n\nExclusion Criteria:\n\n1. Diabetes\n2. Pregnancy\u002Flactation\n3. Hgb \\\u003C11\n4. Current GI obstruction or chronic diarrhea\n5. Subjects who are not within the age range of 18- 65 years.\n6. Evidence of active cardiorespiratory, hepatic, gastrointestinal or renal disease.\n7. History of allergy to the administered drugs.\n8. History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate or affect the interpretation of the results of the study and\u002For any subject unable or unwilling to follow study procedures.\n9. Substance dependence or history of alcohol abuse and\u002For excess alcohol intake\n10. Patients on ketogenic diet\n11. Prisoners or institutionalized individuals\n12. AST (SGOT) \\> 3 times upper limit of normal\n13. ALT (SGPT) \\> 3 times upper limit of normal\n14. History of clinical hypoglycemia documents based on Whipples' triad (ONLY for Aim 2)",true,"ALL","18 Years","65 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. \"Investigational\" means that the has not yet been approved by the U.S. Food \\& Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glucagon.",[27],"Non-Diabetic",[29,30,31],"glucagon","glucose metabolism","bariatric surgery","RECRUITING","2026-05-08",{"date":35,"type":36},"2026-05-11","ACTUAL",{"date":38,"type":36},"2026-02-25",{"date":40,"type":21},"2030-06-30",{"name":42,"class":43},"The University of Texas Health Science Center at San Antonio","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100610888","screening-for-type-2-diabetes-by-oral-glucose-tolerance-test-in-the-population-groups-not-diagnosed-by-fasting-blood-glucose-in-guadeloupe-100610888","NCT07233434","Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe","Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe: a Pilot Study","DIADEG","o Inclusion criteria : Adult subject (over 18 years and under 65 years old) Subjects of African or Indian origin and self-declared Normal FBG levels (110mg\u002FdL) HbA1c levels between 5.7 and 6.4% One or more of the following factors: BMI \\> 25 kg\u002Fm2, family history of T2DM in the 1st and 2nd familial degree, hypertension, dyslipidemia.\n\nAffiliation to the national social health system or equivalent Informed and written consent signed by the patient and the investigator (at the latest on the day of inclusion and before the completion of any research related exam)\n\no Exclusion criteria : Pregnant or lactating woman Women with a history of gestational diabetes Polycystic ovary syndrome Endocrine, hepatic or renal diseases affecting glycemic control Treatment that affect the metabolism of glucose or insulin Refusal to participate Subjects without adequate or impaired decisional abilities for consent to research and placed under guardianship, curatorship or safeguard of justice, person participating in another research including an exclusion period still in progress, severely impaired physical and \u002F or psychological health, which, according to the investigator, may affect the compliance of the study participant",{"count":54,"type":21},120,[56],"NA","In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.",[27],[60,61,62,63,64],"oral glucose tolerance","type 2 diabetes mellitus","Fasting blood glucose","HbA1c","screening","2025-11-14",{"date":67,"type":36},"2025-11-18",{"date":69,"type":36},"2021-02-02",{"date":71,"type":21},"2028-08-02",{"name":73,"class":43},"Centre Hospitalier Universitaire de la Guadeloupe",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":74},"100604797","triglycerides-glucose-index-on-angiographic-profiling-of-non-diabetic-premature-coronary-artery-disease-patients-100604797","NCT07154186","Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients","Impact of Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients","Inclusion Criteria:\n\n* Age ≥18 years old.\n* Both sexes.\n* Non-diabetic patients \\[no history of diabetes, hemoglobin A1C (HbA1C) \\\u003C 6.5%, fasting glucose \\\u003C 126 mg\u002FdL\\].\n* Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography.\n\nExclusion Criteria:\n\n* Known diabetes mellitus (type 1 or type 2).\n* Previous history of coronary revascularization.\n* Severe hepatic or renal dysfunction \\[alanine transaminase (ALT)\u002Faspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)\\\u003C 30 mL\u002Fmin\u002F1.73 m²\\].\n* Malignant disease, autoimmune disease, or systemic inflammatory disorders.\n* Current use of triglyceride-lowering medications.",{"count":83,"type":21},180,"OBSERVATIONAL","This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).",[87,88,27,89,90],"Triglycerides Glucose Index","Angiographic Profiling","Premature","Coronary Artery Disease","2025-09-04",{"date":93,"type":36},"2025-09-05",{"date":91,"type":36},{"date":96,"type":21},"2026-02-01",{"name":98,"class":43},"Sohag University"]